Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENDACT: Bendamustine in iNHL and CLL
NCT01500083Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bendamustine in Indolent Non-Hodgkin Lymphoma (INHL) and chronic lymphocytic leukemia (CLL) (2 cohorts), sponsored by Lundbeck. Primary endpoint: Number of Adverse Events up to 266 days. Started Mar 2012; status: completed.
02
Drugs
bendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01500083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500083.